Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.
CTLA-4 inhibitors
irAEs
liver injury
neutrophil-lymphocyte ratio
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
06
03
2023
received:
07
02
2022
accepted:
07
03
2023
medline:
30
5
2023
pubmed:
20
3
2023
entrez:
19
3
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have proven to be effective treatments for various cancers, but can also elicit immune-related adverse events (irAEs). Given that severe irAEs can be life-threatening, biomarkers that can predict the occurrence of irAEs are of paramount importance. ICIs affect the dynamics of lymphocytes, and alterations in these dynamics may play a role in the development and severity of irAEs. The aim of this study was to investigate the correlation between irAEs and changes in lymphocyte counts. Information on irAEs was collected from 226 ICI cases from 2014 to 2020. We compared lymphocyte counts before treatment and at the onset of irAE and investigated the association between lymphocyte count fluctuations and the presence and severity of irAE, the course after steroid treatment, and overall survival. Of the 226 cases, 27 patients developed grade 3 or higher irAE. Compared to the other groups, the lymphocyte count in this group was significantly decreased at the time of irAE (p < 0.01). There was a trend toward a rapid increase in lymphocyte count in the steroid responder group compared to the non-responder group. Regarding overall survival, patients with irAE had significantly longer survival than those without irAE (p = 0.0025). However, there was no association between changes in lymphocyte count and survival in patients with irAE. The percentage change in lymphocyte count was found to correlate with the incidence of severe irAEs. Close monitoring of the patient's condition is crucial when the lymphocyte count decreases during ICI treatment.
Identifiants
pubmed: 36934436
doi: 10.1002/cam4.5816
pmc: PMC10225184
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10636-10646Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
PLoS One. 2015 Dec 02;10(12):e0143689
pubmed: 26629828
J Gastrointest Oncol. 2018 Feb;9(1):220-224
pubmed: 29564187
J Clin Oncol. 2008 Aug 20;26(24):3913-5
pubmed: 18711176
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Cancer Med. 2023 May;12(9):10636-10646
pubmed: 36934436
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Gastroenterol Hepatol. 2020 Oct;35(10):1782-1788
pubmed: 32187734
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 1988 May;6(5):868-70
pubmed: 3367190
J Clin Oncol. 2017 Dec 1;35(34):3815-3822
pubmed: 28915085
Am Soc Clin Oncol Educ Book. 2018 May 23;38:13-19
pubmed: 30231401
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Invest. 1978 Mar;61(3):703-7
pubmed: 305923
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Ann Intern Med. 1976 Mar;84(3):304-15
pubmed: 769625
Sci Rep. 2021 Jan 14;11(1):1324
pubmed: 33446685
Ann Oncol. 2017 Oct 01;28(10):2496-2502
pubmed: 28961828
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Gastroenterol. 2020 Jun;55(6):653-661
pubmed: 32124082
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Front Oncol. 2021 Jun 29;11:703893
pubmed: 34268127
J Thorac Oncol. 2021 Oct;16(10):1759-1764
pubmed: 34265432
J Dermatol Sci. 2017 Nov;88(2):225-231
pubmed: 28736218
Hepatol Int. 2021 Oct;15(5):1278-1287
pubmed: 34373964
Clin Pharmacol Ther. 2011 Jun;89(6):806-15
pubmed: 21544079
J Am Heart Assoc. 2020 Dec;9(23):e018306
pubmed: 33190570
Semin Oncol. 2015 Aug;42(4):523-38
pubmed: 26320058
J Lab Clin Med. 1978 Apr;91(4):625-34
pubmed: 76667
Eur J Cancer. 2021 Nov;158:217-224
pubmed: 34627664
Int J Mol Sci. 2013 Oct 30;14(11):21463-73
pubmed: 24177566